Peptide delivery into the central nervous system: invasive, physiological and chemical approaches

Bibliography

• GALLOP MA, BARRETT RW, DOWER WJ, FODOR SPA, GORDON EM: Application of combinatorial libraries to drug discovery. 1. Background and peptide combinato-rial libraries. .1 Med. Chem. (1994) 37:1233–1251.
   Google Scholar
• NEWTON CG: Patenting combinatorial libraries and associated technologies. Exp. Opin. Ther. Patents (1996) 6:827–835.
   Web of Science ®Google Scholar
• REESE TS, KARNOVSKY MJ: Fine-structure localization of a blood-brain barrier to exogenous peroxidase. J. Cell. Biol. (1967) 34:207–217.
   PubMed Web of Science ®Google Scholar
• DAVSON H, WELCH K, SEGAL MB: Morphological aspects of the barriers. In: The Physiology and Pathophysiology of the Cerebrospinal Fluid Churchill Livingstone, Edinburgh, UK, (1987) 105–118.
   Google Scholar
• CRONE C: The blood-brain barrier- facts and questions. In: Ion Homeostasis of the Brain Siesjo BK, Sorensen SC (Eds.), Munksgaard, Copenhagen, (1971) 52–62.
   Google Scholar
• PARDRIDGE, WM: Peptide Drug Delivery to the Brain. Raven Press, New York (1991).
   Google Scholar
• BERTLER A, FALCK B, OWMAN C, ROSENGRENN E: The localisation of monoaminergic blood-brain barrier mechanisms. Pharmacol Rev. (1966) 18:369–385.
   PubMed Web of Science ®Google Scholar
• BAUSBACK HH, WARD PE: Kallidin and bradykinin me-tabolism by isolated cerebral microvessels. (1988) Bio-chem. Pharmacol 37:2973–2978.
   Google Scholar
• BROWNLEES J, WILLIAMS CH: Peptidases, peptides, and the mammalian blood-brain barrier. J. Neurochem.(1993) 60:793–803.
   PubMed Web of Science ®Google Scholar
• FRAY A, MECKELEIN B, WEILER-GeTTLER H, MOCKEL B, FLACH R, GASSEN, HG: Pericytes of the brain microvas-culature express y-glutamyl transpeptidase. Eur. j Bio-chem. (1991) 202:421–429.
   Google Scholar
• RISAU W, DINGLER A, ALBRECHT U, DEHOUCK M-P, CECCHELLIR: Blood-brain barr ier perycites are the main source of y-glutamyltranspeptidase activity in brain capillaries. J. Neurochem. (1992) 58:667–672.
   PubMed Web of Science ®Google Scholar
• HEALY DP, WILK S: Localization of immunoreactiveglutamyl aminopeptidase in rat brain. II. Distribution and correlation with angiotensin II. Brain. Res. (1993) 472:165–178.
   Google Scholar
• KUNZ J, KRAUSE D, KREMER M AND DERMIETZEL R: The140-kDa protein of blood-brain barrier-associated peri-cytes is identical to aminopeptidase N. J. Neurochem. (1994) 62:2375–2386.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI T, YAMAGUCHI M, LAJTHA A: Inhibition of dipeptide transport in mouse brain slices. J. Neurol Sci. (1970) 10:323–329.
   PubMedGoogle Scholar
• PARDRIDGE W: Receptor-mediated peptide transport through the blood-brain barrier. Endocrine Rev. (1986) 7:314–330.
   PubMed Web of Science ®Google Scholar
• ZLOKOVIC B, BEGLEY D, SEGAL M, DAWSON H, RAKIC L,LIPOVAC M, MITROVIC DM: Neuropeptide transport mechanisms in the central nervous system. In: Peptide and Amino Add Transport Mechanisms in the Central Nerv-ous System. Rakic L, Begley DJ, Davson H, Zlokovic B (Eds.), MacMillan Press, London (1988):3–19.
   Google Scholar
• SAMII A, BICKEL U, STROTH U, PARDRIDGE WM: Blood-brain barrier transport of neuropept ides: analysis with a metabolically stable dermorphin analogue. Am. J. Physiol. (1994) 267:E124–E131.
   Google Scholar
• DOOLEY CT, CHUNG NN, WILKES BC, SCHILLER PW, PASTERNAK GW, HOUGHTEN RA: An all D-amino acid opioid peptide with central analgesic activity from a combinatorial library. Science (1994) 266:2019–2022.
   PubMedGoogle Scholar
• CORDON-CARDO C etal.: Multidrug-resistant gene p-gly-coprotein is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. LISA (1989) 86:695–698.
   PubMedGoogle Scholar
• TATSUTA T, NAITO M, OH-HARA T, SUGAWARA I, TSURUOT: Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. (1992) 28:20383–20391.
   Google Scholar
• TSUJI A: Peptide delivery across the blood-brain barrier. In: Trends, and Future Perspectives in Peptide and ProteinDrug Delivery Lee WHL, Hashida M, Mizushima Y (Eds.), Harwood Academic Publishers, Chur (Switzerland) (1995):153–174.
   Google Scholar
• CARVEY PM, MAAG TJ, UN D: Injection of biologicallyactive substances into the brain. Methods NeuroscL (1994) 21:214–234.
   Google Scholar
• CAROSCIO JT et al.: A double-blind, placebo-controlled trial of TRH in amyotropic lateral sclerosis. Neurology (1986) 36:141–145.
   PubMed Web of Science ®Google Scholar
• MUNSAT TL, TAFT J, JACKSON IMD: Pharmacokinetics of intrathecal thyrotropin-releasing hormone. Neurology (1987) 37:597–601.
   PubMedGoogle Scholar
• MUNSAT TL et al.: Intrathecal thyrotropin-rel easing hor-mone does not alter the progressive course of ALS: Experience with an intrathecal drug delivery system. Neurology (1992) 42:1049–1053.
   PubMed Web of Science ®Google Scholar
• PASSARO E JR, DEBAS H, OLDENDORF W, YAMADA T: Rapid appearance of intraventricularly administered neuropeptides in the peripheral circulation. Brain Res. (1982) 241:335–340.
   PubMedGoogle Scholar
• MANESS LM, BANKS WA, ZADINA JE, KASTIN AJ: Periven-tricular penetration and disappearance of ICV Tyr-MIF-1, DAMGO, tyrosine, and albumin. Peptides (1995) 17:247–250.
   Google Scholar
• DURHAM DA, BANKS, WA, KASTIN AJ: Carrier-mediated transport of labelled oxytocin from brain to blood. Neuroendocrinology (1991) 53:447–452.
   PubMedGoogle Scholar
• POPLACK DG, BLEYER AW, HOROWITZ ME: Pharmacol-ogy of antineoplastic agents in cerebrospinal fluid. In: Neurobiology of Cerebrospinal Fluid Wood JH (Ed.), Plenum Press, New York (1980):561–578.
   Google Scholar
• DOMB AJ, RINGEL I: Polymeric drug carrier systems in the brain. Methods Neurosci. (1994) 21:169–183.
   Google Scholar
• BREM J, DOMB AJ, LENARTZ D, DUREZA C, OLIVI A, EPSTEIN JI: Brain biocompatibility of a biodegradable controlled release polymer consisting of anhydride copolymer of fatty acid dimer and sebacic acid. J. Controlled Release (1992) 19:325–329.
   Google Scholar
• KREWSON CE, SALTZMAN, WM: Targeting of proteins in the brain following release from a polymer. In: Trends, and Future Perspectives in Peptide and Protein Drug Delivery Lee WHL, Has hida M, Mizushima Y (Eds.), Harwood Aca-demic Publishers, Chur (Switzerland) (1995)273–294.
   Google Scholar
• POVVELL EM, SOBARZO MR, SALTZMAN WM: Controlled release of nerve growth factor from a polymeric im-plant. Brain Res. (1990) 515:309–311.
   PubMedGoogle Scholar
• MENDEZ A, CAMARATA PJ, SURYANARAYANAN R, EBNER TJ: Sustained intracerebral delivery of nerve growth factor with biodegradable polymer microsphere s. Meth-ods Neurosci. (1994) 21:150–168.
   Google Scholar
• BO NETT I A, KIM S: P hat- macokinetics of an extended-re-lease human interferon alpha-2b formulation. Cancer Chem other. Pharmacol. (1993) 33:258–261.
   PubMedGoogle Scholar
• LYSAGHT MJ, FRYDEL B, GENTILE F, EMERICH D, WINN S: Recent progress in immunoisolated cell therapy. J. Cell. Biochem. (1994):196–203.
   PubMedGoogle Scholar
• NEUWELT E, KROLL RA: Osmotic blood-brain barrier modification: Increasing delivery of diagnostic and therapeutic agents to the brain. Methods NeuroscL (1994) 21:52–67.
   Google Scholar
• NEUWELT EA et al Increased delivery of tumour-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with mela-noma metastatic to the central nervous system. Neuro-surgery (1987) 20:885–895.
   PubMedGoogle Scholar
• NEUWELT EA et al.: Delivery of virus-sized iron oxide particles to rodent CNS neurones. Neurosurgery (1994) 34:777–784.
   PubMed Web of Science ®Google Scholar
• GUMERLOCK MK, NEUVVELT EA: Therapeutic opening of the blood-brain barrier in man. In: Physiology and Phar-macology of the Blood-Brain Barrier. Bradbury MVVB (Ed.), Springer, Berlin (1992):525–542.
   Google Scholar
• RAYMOND JJ, ROBERTSON DM, DINSDALE HB: Pharma-cological modification of bradykinin induced break-down of the blood-brain barrier. Can. J. Neurol ScL (1986) 13:214–220.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM: Vector-mediated peptide delivery to the brain. Adv. DrugDeliv. Rev. (1995) 15:109–146.
   PubMed Web of Science ®Google Scholar
• FUKUTA M, OKADA H, IINUMA S, YANAI S, TOGUCHI H:Insulin fragments as a carrier for pEptide delivery across the blood-brain barrier. Pharm. Res. (1994) 11:1681–1688.
   PubMedGoogle Scholar
• ITO F, ITO S, SHIMIZU N: Transmembrane delivery ofpolypeptide hormones bypassing the intrinsic cell sur-face receptors: a conjugate of insulin with alpha 2-macroglobul in (alp ha 2M) recognizing bothinsulin and alpha 2M receptors and its biological activity in relation to endocytic pathways. Mol. Cell Endocrinol (1984) 36:165–173.
   PubMedGoogle Scholar
• SKARLATOS S, YOSHIKAWA T, PARDRIDGE WM: Trans-port of [125 ritransferrin through the rat blood-brain barrier. Brain Res. (1995) 683:164–171.
   PubMed Web of Science ®Google Scholar
• RASO V, BASALA M: A highly cytotoxic human transfer-rin-ricin A chain conjugate used to select receptor-modified cells. J Biol. Chem. (1984) 259:1143–1149.
   PubMed Web of Science ®Google Scholar
• KUMAGAI AK, EISENBERG J, PARDRIDGE WM: Adsorp-tive-mediated endocytosis of cationised albumin and a B-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport J Biol. Chem. (1987) 262:15214–15219.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM, TRIGUERO D, BUCIAK JL: I3-Endorphin chimeric peptides: Transport through the blood-brain barrier and cleavage of disulfide linkage by brain. Endocrinology (1990) 126:977–984.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM, TRIGUERO D, BUCIAK J, YANG J: Evalu-ation of cationised rat albumin as a potential blood-brain barrier drug transport vector. J. Pharmacol Exp. Ther. (1990) 255:893–899.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM, BUCIAK JL, FRIEDEN, PM: Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier. j Pharmacol. Exp. Ther. (1991) 259:66–70.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM, KANG Y-S, BUCIAK JL, YANG J: Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. (1995) 6:807–816.
   Google Scholar
• YOSHIKAWA T, PARDRIDGE WM: Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J. Pharmacol Exp. Ther. (1992) 263:897–903.
   PubMed Web of Science ®Google Scholar
• FRIEDEN PM et al.: Blood-brain barrier conjugation and in vivo activity of an NGF conjugate. Science (1993) 259:373–377.
   PubMed Web of Science ®Google Scholar
• GRANHOLM A-C etal: NGF and anti-transferrin receptor antibody conjugate: short and long-term effects on survival of cholinergic neurones in intraocular septal transplants. J. Pharmacol. Exp. Ther. (1994) 268:448–459.
   PubMedGoogle Scholar
• GREEN NM: Avidin and streptavidin. Methods Enzymol. (1990) 184:51–67.
   PubMed Web of Science ®Google Scholar
• KANG Y-S, SAITO Y, PARDRIDGE WM: Pharmacokinetics of [3H]biotin bound to different avidin analogues. J. Drug Target. (1995) 3:159–165.
   PubMedGoogle Scholar
• BICKEL U, YAMADA S, PARDRIDGE WM: Synthesis and bioactivity of monobiotinylated DALDA: a mu-specific opioid peptide designed for targeted brain delivery. J. Pharmacol Exp. Ther. (1994) 268:791–796.
   PubMed Web of Science ®Google Scholar
• BICKEL U, KANG Y-S, PARDRIDGE WM: In vivo cleavabil-ity of a disulfide-based chimeric opioid peptide in rat brain. Bioconj Chem. (1995) 6:211–218.
   PubMedGoogle Scholar
• BICKEL U, YOSHIKAWA T, LANDAW EM, FAULL K.F, PAR-DRIDGE WM: Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. USA (1993) 90:2618–2622.
   PubMed Web of Science ®Google Scholar
• WU D, PADRIDGE WM: Central nervous system pharmacologic effect in conscious rats after intravenous injec-tion of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J. Pharmacol. Exp. Ther. (1996) 279:77–83.
   PubMed Web of Science ®Google Scholar
• SAITO Y, BUCIAK J, YANG J, PARDRIDGE WM: Vector-me-diated delivery of 125I-labeled B-amyloid peptide AI31-40 through the blood-brain barrier and binding to Alzhe-imer disease amyloid of the 41-40/vector complex. Proc. Natl. Acad. Sci. USA (1995) 92:10227–10231.
   PubMed Web of Science ®Google Scholar
• BANKS WA, KASTIN AJ: Peptides and the blood-brain barrier: lip ophilicity as a predictor of permeability. Brain. Res. Bull. (1985) 15:287–292.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM, TRIGUERO D, YANG J, CANCILLA PA: Comparison of in vitro and in vivo models of drug transcytosis through the blood-brainbarrier. . J. Pharma-col. Exp. Ther. (1990) 253:884–891.
   PubMed Web of Science ®Google Scholar
• PATEL HM: Liposomes: bags of challenge. Biochem. Soc. Trans. (1984) 12:333–335.
   PubMedGoogle Scholar
• HOFFMAN PL, WALTER R, BULAT M: An enzymatically stable peptide with activity in the central nervous system: its penetration through the blood-CSF barrier. Brain Res. (1977) 122:87–94.
   PubMed Web of Science ®Google Scholar
• BUNDGAARD H: The utility of the prodrug approach to improve peptide absorption. J. Conn-oiled Release (1992) 21:63–72.
   Google Scholar
• BUNDGAARD H: Prodrugs as a means to improve the delivery of peptide drugs. Adv. Drug Deily. Rev. (1992) 8:1–38.
   Web of Science ®Google Scholar
• MOSS J: Peptide prodrugs designedto limit metabolism. In: Peptide-Based Drug Design. Taylor MD, Amidon GL (Eds.), American Chemical Society, Washington, DC (1995)421–448.
   Google Scholar
• BREWSTER D: Species variations in TRH inactivation: advantages of stable analogues. In: Thyrotropin-Releasing Hormone. Griffiths EC, Bennett GW (Eds.), Raven Press, New York (1983):109–118.
   Google Scholar
• MURANISHI S et al: Lipophilic peptides: lauroyl thy-rotropin releasing hormone and its biological activity. Pharm. Res. (1991) 5:649–652.
   Google Scholar
• BUNDGAARD H, MOSS J: Prodrugs of peptides. 4. Biore-versible derivatives of thyrotropin-releasing hormone (TRH) with increased lipiphilicity and resistance to cleavage by TRH-specific serum enzyme. Pharm. Res. (1990) 7:885–892.
   Google Scholar
• TSUZUKI N, HAMA T, HIBI T, KONISHI R, FUTAKI S,KITAGAWA K: Adamantane as a brain-directed drug carrier for poorly absorbed drug: antinociceptive ef-fects of [D-A1a2]leu-enkephalin derivatives conjugated with the 1-adamantane moiety. Biochem. Pharmacol (1991) 41:R5–R8.
   Google Scholar
• GREENE D et al: Enkephalin analog prodrugs: assess-ment of in vitro conversion, enzyme cleavage charac-terisation and blood-brain barrier permeability. J. Pharmacol. Exp. Ther. (1996) 277:1366–1375.
   PubMedGoogle Scholar
• MISICKA A, MASZCZYNSKA I, LIPKOWSKI AW, ST ROPOVA D, YAMAMURA HI, HRUBY VJ: Synthesis and biological properties of gamma-glutamyl-dermorphin, a prodrug. Life Sci. (1996) 58:905-911. BODOR N, PROKAI L: Molecular packaging. Peptide delivery to the central nervous system by sequential metabolism. In: Peptide-Based Drug Design. Taylor MD, Amidon GL (Eds.), American Chemical Society, Washington, DC (1995):317–337.
   Google Scholar
• BODOR N, BREWSTER ME: Chemical delivery systems. In: Handbook of Experimental Pharmacology Vol. 100, Targeted Drug Delivery Juliano RL (Ed.), Springer-Verlag, Berlin (1990:231–284.
   Google Scholar
• BODOR N, PROKAI L, WU W-M, FARAG H, JONNALA- GADDA S, KAWAMURA T, SIMPKINS, J: A strategy for delivering peptides into the central nervous system by sequential metabolism. Science (1992) 257:1698–1700.
   PubMed Web of Science ®Google Scholar
• BODOR N, PROKAI L: Delivery of peptides into the central nervous system by sequential metabolism. In: Peptides: Chemistry, Structure and Biology. Hodges RS, Smith JA (Eds.), ESCOM Science Publishers, Leiden (1994):830–833.
   Google Scholar
• SIMPKINS JW, OUYANG X, PROKAI L, BODOR N: Delivery of peptides into the central nervous system by molecu-lar packaging and sequential metabolism as a method of altering neuropeptide activity during ageing. Neuro-protocols: A Companion to Methods in Neurosciences (1994) 4:225–234.
   Google Scholar
• PROKAI-TATRAI K, PROKAI L, BODOR N: Brain-targeted delivery of a leucine-enkephaline analogue by retrometabolic design. J. Med. Chem. (1996) 39:4775–4782.
   PubMed Web of Science ®Google Scholar
• PROKAI L, OUYANG X, WU W-M, BODOR N: Chemical delivery system to transport a pyroglutamyl peptide amide to the central nervous system. J. Am. Chem. Soc. (1994) 116:2643–2644.
   Google Scholar
• PROKAI L: Delivery of peptides into the central nervous system. Drug Discovery Today (1996) 1:161–168.
   Google Scholar